These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35163087)

  • 1. P-Glycoprotein and Androgen Receptor Expression Reveals Independence of Canine Prostate Cancer from Androgen Hormone Stimulation.
    Cavalca AMB; Brandi A; Fonseca-Alves RH; Laufer-Amorim R; Fonseca-Alves CE
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
    Sabnis NG; Miller A; Titus MA; Huss WJ
    Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.
    Fedoruk MN; Giménez-Bonafé P; Guns ES; Mayer LD; Nelson CC
    Prostate; 2004 Apr; 59(1):77-90. PubMed ID: 14991868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
    PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
    Dai JL; Maiorino CA; Gkonos PJ; Burnstein KL
    Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
    Nyquist MD; Ang LS; Corella A; Coleman IM; Meers MP; Christiani AJ; Pierce C; Janssens DH; Meade HE; Bose A; Brady L; Howard T; De Sarkar N; Frank SB; Dumpit RF; Dalton JT; Corey E; Plymate SR; Haffner MC; Mostaghel EA; Nelson PS
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
    Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
    Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Castration-recurrent prostate cancer is not androgen-independent.
    Mohler JL
    Adv Exp Med Biol; 2008; 617():223-34. PubMed ID: 18497046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
    Eikenberry SE; Nagy JD; Kuang Y
    Biol Direct; 2010 Apr; 5():24. PubMed ID: 20406442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
    Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
    Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.
    D'Antonio JM; Vander Griend DJ; Antony L; Ndikuyeze G; Dalrymple SL; Koochekpour S; Isaacs JT
    PLoS One; 2010 Jul; 5(7):e11475. PubMed ID: 20628607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
    Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells.
    Kollara A; Diamandis EP; Brown TJ
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):493-502. PubMed ID: 12767274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3.
    Tilley WD; Bentel JM; Aspinall JO; Hall RE; Horsfall DJ
    Steroids; 1995 Jan; 60(1):180-6. PubMed ID: 7792809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.